CTOs on the Move


 
Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient`s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.kariusdx.com
  • 975 Island Drive Suite 101
    Redwood City, CA USA 94065
  • Phone: 866.452.7487

Executives

Name Title Contact Details
Hamed A
Vice President of Engineering, Information Security Officer Profile

Funding

Karius raised $50M on 08/05/2017
Karius raised $25M on 11/30/2018
Karius raised $165M on 02/24/2020

Similar Companies

Saskatchewan Research Council

Saskatchewan Research Council is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Forticell Bioscience

Forticell Bioscience is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xpogen

Xpogen is a Newton Center, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atomwise

Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster.

Regenacy Pharmaceuticals

Regenacy Pharmaceuticals is developing a novel, disease-modifying approach to treating peripheral neuropathies that goes beyond pain and symptom management to restore peripheral nerve function.